Menu
Washingtoner
  • Home
  • Business
  • Technology
  • Health
  • Construction
  • Arts
  • Information Technology
  • Transportation
  • Home
Washingtoner

First Choice Neurology Pioneering Neurologists Administer the New FDA-Approved Drug Kisunla
Washingtoner/10263199

Trending...
  • Wealthywet's Miami Swim Week 2025 Debut Signals a New Era of Luxury in Swimwear
  • Emerge Apps Launches Mod Performance Suite: A New Era of Work Comp Selling for Insurance Agents
  • Advanced Solar Space Technology; Record Efficiency of 15.7%; Agreement to Provide NOVI Space with Rollable PV Array Blankets for Space Launch in 2026
Kisunla FDA Approved for Alzheimers
JUPITER, Fla. - Washingtoner -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum are among the first physicians in the country to administer the newly FDA-approved drug Kisunla to patients. This groundbreaking development marks a significant milestone in neurological care, offering new hope to patients battling a range of neurological conditions.

Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.

He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."

More on Washingtoner
  • The Somm. Hotel at Harvest to Host Auction of Washington Wines Gala Event
  • DivX Enhances AVI Playback Resources; Simplifies Guide to Playing AVI Files with DivX Software
  • Patrick Aloni Joins Historic Gold and Copper Discovery in Argentina with Multimillion-Dollar Stake
  • Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures
  • AI-Powered Retail Media Platform PulseAd Enters $280B US Market with Seattle Operations

Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."

Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent.  We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."

The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.

More on Washingtoner
  • Spokane: 2025 Pools
  • Goldstar Rehabilitation Celebrates 15 Years of Early Intervention Across Southeastern PA
  • United States Congressional Candidate Peter Coe Verbica Unveils 25-Point Federal Plan to Help Make California Affordable Again
  • D8Averse Launches D8Acapture: Disruptive Mobile-First App Transforms Utility Pole Data Collection
  • Experience Trembling Firsthand with the New AgeMan® Tremor Simulator

About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.

For more information about Kisunla and First Choice Neurology, visit fcneurology.com

Contact
First Choice Neurology
***@fcneurology.net


Source: First Choice Neurology

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Vice President JD Vance & Industry Leaders at Bitcoin Conference After Partnership Signing to Optimize Cybersecurity Solutions: Bullet Blockchain, Inc
  • Actress/Comedian Schelle Purcell Sizzles This Summer with Star-Making Turn in Tyler Perry's #1 Netflix Film, Straw, and Upcoming Comedy Special
  • Braxus Entertainment Group Acquires All Star Events
  • Global Expansion Fueled via Agreement to Take 90% Ownership of Nook Holdings UAE-Based Sports Incubator by Online Lottery & Sports Game Provider
  • Remember Internet Pioneers NetCom Solutions & Network Solutions? Founder Emmit J. McHenry is Now Leading the Emerging Cybersecurity Firm Cycurion
  • Celebrating Father's Day Weekend with Free Admission for the entire Family, AKC Dog Show, Best in Show and Puppy Event, Product Vendors
  • LIB Continuous Innovation: Custom Rain Test Chambers & IP Labs
  • csky.ai & DuoKey Launch Secure AI Transcription Solution for Microsoft 365
  • PlayClay.io Launches Streamlined Quoting Platform for Manufacturers' Reps and Distributors
  • From Hotel Discomfort to Bamboo Bliss: BedVoyage Redefines Travel Sleep
  • Nordstrom Rack to Open New Location in Pompano Beach, FL
  • Let's Talk Series: At the Crossroads: Immigration Today
  • Cyta Cyprus Selects Axiros' AXESS Platform for Cloud-Native, Data-Driven Device Management
  • Spokane: City Provides Annual Report on Drinking Water Quality
  • DealMagik Successfully Concludes National Floral Design Contest with Over 150 Submissions
  • Behavioral Health Advocates to Hold Joint Capitol Hill Press Conference on June 11
  • VNBTC Becomes The Top Crypto Investment Platform As Its Bitcoin Cloud Mining Solution Goes Viral
  • Advanced Solar Space Technology; Record Efficiency of 15.7%; Agreement to Provide NOVI Space with Rollable PV Array Blankets for Space Launch in 2026
  • Urgent Reform Demanded to Stop Child Abuse in Youth Behavioral Facilities
  • Cyrus O'Leary's Mini Cream Pies - The Latest Dessert Innovation from Sara Lee Frozen Bakery Delivers Indulgence in Single-Servings
_catLbl0 _catLbl1

Popular on Washingtoner

  • City of Spokane, City of Spokane Valley Sign Interlocal Agreement with Spokane County to Coordinate Homelessness Response - 2295
  • Assent Launches Carbon Border Adjustment Mechanism Solution to Help Manufacturers Meet Regulatory Requirements - 207
  • 150% Increase in Fiscal Q2 Sales vs Previous Year to $750,000; Continuous Record Quarters & Profitability for Homebuilding Product: Innovative Designs - 204
  • Sequentex Achieves OMNIA Partners Approval, Empowering Public Sector and other Agencies with Streamlined Technology Procurement - 202
  • The Great Reset, the First Photorealistic AI Film Makes History at the Cannes Film Festival - 185
  • Perspectives: Jellyfish Publication of an exciting new human clinical trial of proprietary KollaJell™ collagen peptide formulation - 151
  • Deadline Extended: More Time to Submit Your Proposal for the OpenSSL Conference 2025 - 124
  • Juventix Regenerative Medical Announces Strategic Partnership with Juvasonic® to Expand Needle-Free Biologic Delivery Platform - 120
  • Travel Industry Sounds Alarm: Expedia and Leaders Confront U.S. Tourism Concerns - 111
  • Award-winning NJ Author Celebrates New Release and Multi-Author Collaboration - 101

Similar on Washingtoner

  • Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures
  • Goldstar Rehabilitation Celebrates 15 Years of Early Intervention Across Southeastern PA
  • Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
  • LIB Continuous Innovation: Custom Rain Test Chambers & IP Labs
  • PlayClay.io Launches Streamlined Quoting Platform for Manufacturers' Reps and Distributors
  • Behavioral Health Advocates to Hold Joint Capitol Hill Press Conference on June 11
  • Urgent Reform Demanded to Stop Child Abuse in Youth Behavioral Facilities
  • Mental Health Watchdog Calls Baker Acting of Children in Florida a Parental Rights Violation
  • Kaplan Morrell Applauds Passage of Landmark Workers' Compensation Reform in Colorado
  • $750 Million Market Projected to Reach $3.3 Billion Globally in 2034 for New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharma, Inc
Copyright © 2025 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute